Marksans Pharma share price
You have to be logged in to add this to Watchlist.- ₹181.70(0.08%)February 18, 2026 15:28:34 PM IST
- NSE
- BSE
- Vol : 391.43 K (NSE + BSE)Last 20 day avg : 998.06 K
Marksans Pharma is trading 0.08% upper at Rs 181.70 as compared to its last closing price. Marksans Pharma has been trading in the price range of 183.05 & 179.70. Marksans Pharma has given 0.69% in this year & -2.91% in the last 5 days. Marksans Pharma has TTM P/E ratio 22.65 as compared to the sector P/E of 24.10.There are 2 analysts who have initiated coverage on Marksans Pharma. There are 1 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 113.20 Crores in its last quarter.Listed peers of Marksans Pharma include Cipla (0.35%), Sun Pharmaceutical Industries (0.44%), Torrent Pharmaceuticals (-1.20%).The Mutual Fund holding in Marksans Pharma was at 4.41% in 31 Dec 2025. The MF holding has increased from the last quarter. The FII holding in Marksans Pharma was at 8.13% in 31 Dec 2025. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Updated on Feb 18, 2026, 04:44 PM UTC
- BetaHigh volatility1.55Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.13The debt-to-equity ratio, indicating a company's financial leverage.
- Dividend YieldLower than industry0.45Annual dividends as a percentage of the stock price.
- PEG RatioIndicates undervaluation0.97The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
- P/E-Price-to-earnings ratio based on trailing 12-month earnings
- P/B-The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
|
| ||||
|
| ||||
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Cipla | Neutral | 1,348.00 | 0.35 | 1,08,868.58 | 22.95 | 3.87 | 0.87 | 0.81 |
| Sun Pharmaceutical Industries | Bullish | 1,724.90 | 0.44 | 4,13,586.64 | 36.24 | 5.77 | 0.92 | 0.50 |
| Torrent Pharmaceuticals | Bullish | 4,207.50 | -1.20 | 1,42,269.92 | 67.32 | 17.1 | 0.83 | 17.62 |
| Divi's Laboratories | Neutral | 6,270.00 | 1.37 | 1,66,233.79 | 78.61 | 11.52 | 0.46 | 0.01 |
| Dr Reddy's Laboratories | Bullish | 1,283.00 | -0.16 | 1,07,061.40 | 18.63 | 3.14 | 0.63 | 2.34 |
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2026-02-05 | Quarterly Results |
| 2025-11-13 | Quarterly Results |
| 2025-08-12 | Quarterly Results |
| 2025-05-19 | Audited Results & Final Dividend |
| 2025-02-11 | Quarterly Results |
- IndustryBiotechnology & Drugs
- ISININE750C01026
- BSE Code524404
- NSE CodeMARKSANS
Marksans Pharma is trading at 181.70 as on Wed Feb 18 2026 09:58:34. This is 0.08% upper as compared to its previous closing price of 181.55.
The market capitalization of Marksans Pharma is 8245.34 Cr as on Wed Feb 18 2026 09:58:34.
The average broker rating on Marksans Pharma is Strong Buy. The breakup of analyst rating is given below -
- 1 analysts have given a strong buy rating
- 1 analysts have given a buy rating
- 0.00 analysts have given a hold rating
- 0.00 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Marksans Pharma is 270.60 whereas the 52 wk low is 157.25
Marksans Pharma can be analyzed on the following key metrics -
- TTM P/E: 22.65
- Sector P/E: 24.10
- Dividend Yield: 0.44%
- D/E ratio: -
Marksans Pharma reported a net profit of 380.58 Cr in 2025.
The Mutual Fund Shareholding was 4.41% at the end of 31 Dec 2025.